【摘要】 目的　建立监测乳腺癌患者病情变化的有效指标 ,探讨影响患者血清CEA、CA15 3浓度的机制。方法　用IRMA和酶免疫法检测 2 0 0例未处置乳腺癌患者血清CEA、CA15 3含量。结果　乳癌患者血清CEA、CA15 3异常含量分别为 14 %和 2 0 % ,两种肿瘤标志物与肿瘤的大小及淋巴结的浸润有关 ,大肿瘤和淋巴结浸润患者的CEA、CA15 3浓度明显增高 ,CEA还与组织型别有关。单变量预后评价显示 :肿瘤的大小、淋巴结浸润、组织型别、CEA、CA15 3等是无病存活的预后要素。结论　肿瘤标志物CEA、CA15 3是评估乳癌患者预后的有效指标更多还原

【Abstract】 Objective To established invalidated index for monitoring illness in patients with Breast Cancer, to discuss the mechanisms influencing the serum concentrations of CEA and/or CA15 3. Methods CA15 3 and CEA were determined by IRMA and ELISA in 200 untreated patients with Locoregional Breast Cancer. Results Abnormal CA15 3 and CEA serum levels were found in 14% and 20% of patients. Both tumor markers were correlated with tumor size and nodal involvement, with significantly higher concentrations in patients with larger tumors or to the histological type. Univariate prognostic evaluation showed that tumor size, nodal involvement, histological grade, CA15 3 and CEA were prognostic factors in disease-free survival. Conclusion Tumor markers are useful tools in the prognostic evaluation of patients with breast cancer.更多还原